Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients
Latest Information Update: 02 Sep 2026
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Iberdomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 08 May 2026 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2022 New trial record